La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ikena Oncology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ikena Oncology..

Ikena Oncology (NASDAQ:IKNA) Azioni, Catena delle Opzioni

Ikena Oncology

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Ikena Oncology Inc

During the last three months, 4 analysts shared their evaluations of Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $31.25, a high estimate of $33.00, and a low estimate of $30.00. This current average has increased by 6.55% from the previous average price target of $29.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096158_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Artivion among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Artivion. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Artivion compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Artivion's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Artivion's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AORT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Artivion analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Artivion</h2>
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
<h3>Unraveling the Financial Story of Artivion</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Artivion's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.82% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Artivion's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.72%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Artivion's ROA excels beyond industry benchmarks, reaching -0.27%. This signifies efficient management of assets and strong financial health.
Debt Management: Artivion's debt-to-equity ratio stands notably higher than the industry average, reaching 1.23. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

AORT

Where Artivion Stands With Analysts

Analysts' ratings for Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $35.0, a high estimate of $38.00, and a low estimate of $30.00. Highlighting a 14.63% decrease, the current average has fallen from the previous average price target of $41.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096150_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Yelp by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nitin Bansal</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Yelp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Yelp compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Yelp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Yelp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/YELP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Yelp analyst ratings.</a>
<h2>All You Need to Know About Yelp</h2>
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making better buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States.
<h3>Yelp: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Yelp's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 5.9%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.65%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Yelp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.88%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YELP

4 Analysts Assess Yelp: What You Need To Know

Throughout the last three months, 6 analysts have evaluated Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Corteva, presenting an average target of $67.17, a high estimate of $71.00, and a low estimate of $62.00. This upward trend is apparent, with the current average reflecting a 5.61% increase from the previous average price target of $63.60.
<img src="https://www.benzinga.com/files/images/story/2024/1731096140_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Corteva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Corteva. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Corteva's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Corteva's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corteva analyst ratings.</a>
<h2>Get to Know Corteva Better</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>Key Indicators: Corteva's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Corteva's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -61.94%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Corteva's net margin excels beyond industry benchmarks, reaching -22.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corteva's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.1%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Corteva's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Corteva's debt-to-equity ratio is below the industry average at 0.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

Analyst Ratings For Corteva

Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) has been analyzed by 19 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.79, a high estimate of $82.00, and a low estimate of $47.00. This current average has increased by 16.51% from the previous average price target of $55.61. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096133_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Zillow Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$64.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$82.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Mike Burton</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Zillow Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zillow Gr compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Zillow Gr's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zillow Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zillow Gr analyst ratings.</a>
<h2>Unveiling the Story Behind Zillow Gr</h2>
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.
<h3>A Deep Dive into Zillow Gr's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Zillow Gr's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 17.14%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Zillow Gr's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Zillow Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.31%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.25, Zillow Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Zillow Gr

Across the recent three months, 3 analysts have shared their insights on Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Synaptics, presenting an average target of $105.0, a high estimate of $130.00, and a low estimate of $90.00. Highlighting a 5.97% decrease, the current average has fallen from the previous average price target of $111.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096125_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Synaptics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Synaptics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Synaptics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Synaptics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SYNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Synaptics analyst ratings.</a>
<h2>Delving into Synaptics's Background</h2>
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.
<h3>Synaptics: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Synaptics showcased positive performance, achieving a revenue growth rate of 8.84% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Synaptics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 84.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Synaptics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 15.42%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Synaptics's ROA stands out, surpassing industry averages. With an impressive ROA of 7.77%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Synaptics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.7.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SYNA

The Analyst Landscape: 3 Takes On Synaptics

Throughout the last three months, 17 analysts have evaluated Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Best Buy Co, presenting an average target of $105.35, a high estimate of $123.00, and a low estimate of $80.00. This upward trend is evident, with the current average reflecting a 11.19% increase from the previous average price target of $94.75.
<img src="https://www.benzinga.com/files/images/story/2024/1731096118_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Best Buy Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$107.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Elizabeth Suzuki</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Best Buy Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Best Buy Co's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Best Buy Co analyst ratings.</a>
<h2>About Best Buy Co</h2>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Best Buy Co: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Best Buy Co's revenue growth over a period of 3 months has faced challenges. As of 31 July, 2024, the company experienced a revenue decline of approximately -3.08%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.13%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Best Buy Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.92%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.32, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Best Buy Co In The Eyes Of 17 Experts

Shares of metals and materials companies are trading lower. The market may be reacting to China's recent stimulus efforts which have struggled to buoy the economy and business conditions.
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;

WIIM

IGMS

IGM Biosciences shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) is reportedly considering the sale of Jeppesen, a navigation unit it acquired in 2000, to reduce its $58 billion debt. <a href="https://www.bloomberg.com/news/articles/2024-11-08/boeing-is-exploring-possible-6-billion-sale-for-jeppesen-unit?srnd=homepage-americas">Bloomberg reported </a>that the company is working with an adviser on a sale that could bring in more than $6 billion. 
The unit, which provides navigation tools to airlines, has already attracted interest from many private equity firms.
The possible divestment follows CEO Kelly Ortberg's review of Boeing's assets to identify units that may no longer align with the company&#8217;s focus on core commercial aircraft production. Ortberg said in an earnings call that he's looking at "whether a business or product fits with the long-term strategy or whether it would be better off someplace else."
Ortberg also confirmed that Boeing will pay employees furloughed during the seven-week strike in Seattle, according to a <a href="https://www.bnnbloomberg.ca/business/company-news/2024/11/08/boeing-ceo-says-furloughed-workers-will-be-paid-for-lost-time/#:~:text=%E2%80%9CAs%20we%20navigated%20through%20the,first%20weeks%20of%20his%20tenure.">BNN Bloomberg report.</a> "We want to acknowledge your support by returning your lost pay," the CEO said in an internal memo. 
However, the company plans more job cuts to reduce costs. Boeing has already been cutting costs with hiring freezes and corporate travel reductions to handle its cash shortage.
BA Price Action: Boeing shares were up 0.67% at $151.99 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png" alt="" class="wp-image-638240" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1.png 1185w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41853052/how-much-is-nintendo-suing-palworld-for-patents-financial-details-unveiled">How Much Is Nintendo Suing Palworld For? Patents, Financial Details Unveiled</a></li>
</ul>
Image Via Shutterstock.

News

Movers

What's Going On With Boeing Shares Today?

Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) are climbing following reports <a href="https://www.benzinga.com/news/24/10/41383838/expedia-shares-rises-by-around-6-whats-going-on">of a potential buyout.</a>
With the stock now overbought, there's a strong chance it could reverse and trend lower. That&#8217;s why our team of trading experts has selected it as our Stock of the Day.
Typically, a stock remains within its usual trading range. However, when investors and traders turn emotional and aggressively buy, they can drive the price above this range. In such cases, the stock is considered &#8220;overbought.&#8221;
Many trading strategies and styles are based on the concept of reversion to the mean. If a stock is overbought, people may start to sell it and this could push the price lower.
There are dozens if not hundreds of ways to measure momentum. They are called indicators. It is important to understand that they are different ways of measuring the same thing. New traders can overcomplicate things by studying too many of them.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41402089/goldman-sachs-highlights-20-top-short-squeeze-opportunities-for-q3-earnings-season">Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season</a>
Some traders have had success by using and mastering just a few of these indicators.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1024x530.webp" alt="" class="wp-image-638424" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1024x530.webp 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-300x155.webp 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-768x397.webp 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1536x795.webp 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart.webp 1585w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The red line on the chart is called a Bollinger Band. It is two standard deviations above the 20-day moving average. This is important because according to statistics and probability theory, 95% of all trading should be within two standard deviations of the mean.
If a stock exceeds this threshold, as Expedia has done, it will draw sellers into the market. They will be expecting a reversion back towards the average and their selling could put pressure on it.
On the bottom part of the chart is the Relative Strength Index (RSI). It is another way to measure momentum. If the blue line exceeds the horizontal red line, it indicates overbought conditions. As you can see, that is the case now. This could also draw sellers into the market.
Other popular momentum indicators include Moving Average Convergence Divergence (MACD), the Commodity Channel Index (CCI), and Stochastics (TAS). These are all available on <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Many rookie traders make things more complicated than they need to be. Part of this is using too many indicators. It may make sense for some traders to only use a few and to become familiar and comfortable with them.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41849984/powell-brushes-off-trumps-removal-threat-economists-say-2026-could-be-his-last-stand">Powell Brushes Off Trump&#8217;s Removal Threat: Economists Say 2026 Could Be His Last Stand</a></li>
</ul>
Photo: II.studio/Shutterstock.com

Technicals

Travel

Trading Ideas

EXPE

Stock Of The Day: Expedia Appears Overbought And May Reverse

GATO

GOLD

PAAS

SAND

SBSW

Shares of metals and materials companies are trading lower. The sector may be reacting to China's recent stimulus efforts which have struggled to buoy the economy and business conditions.

In the current session, the stock is trading at $116.60, after a 0.46% increase. Over the past month, e.l.f. Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) stock increased by 8.49%, and in the past year, by 22.36%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1731095785_0.png" alt="Past Year Chart" />

<h3>Comparing e.l.f. Beauty P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 49.61 in the Personal Products industry, e.l.f. Beauty Inc. has a higher P/E ratio of 62.74. Shareholders might be inclined to think that e.l.f. Beauty Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731095785_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into e.l.f. Beauty Inc's Price Over Earnings

Salesforce shares are trading higher after the company announced it will hire 1,000 people for an "AI product sales push" and is also developing artificial intelligence agents.

Merck (NYSE:&nbsp;MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR&#xAE; (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.
Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in PAH patients.

Global

Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II Or III

Gray Television shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, the company said it's carefully evaluating capital expenditure needs for 2025 and announced its board approved an increase in its debt repurchase authorization.

TD Cowen analyst Andrew Charles maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Hold and raises the price target from $18 to $21.

Price Target

FWRG

TD Cowen Maintains Hold on First Watch Restaurant Gr, Raises Price Target to $21

DVAX

Dynavax Technologies shares are trading higher after the company reported better-than-expected Q3 EPS results and launched a $200 million share buyback program. HC Wainwright & Co. reiterated a Buy rating on the stock.

Benchmark analyst Robert Wasserman maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and raises the price target from $110 to $135.

LGND

Benchmark Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $135

<a href="https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push" title="https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push">https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push</a>
&nbsp;
Salesforce Inc. plans to hire more than 1,000 workers to sell its new generative AI agent product.&nbsp;

Management

"Salesforce To Hire 1,000 People For AI Product Sales Push; Company To Take Advantage Of AI 'Momentum,' CEO Says; Rivals Also Developing Artificial Intelligence Agents" - Bloomberg News

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy and raises the price target from $95 to $115.

ACLX

HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $115

We revise our guidance
Due to higher-than-expected inflation in the second half of the year, we have revised our year-end inflation forecast upwards. Accordingly, we are updating our revenue growth target5 for 2024 to approximately 7%. We maintain our EBITDA margin expectation at approximately 42% and our operational capex to sales6 ratio target at approximately 23%.
I extend my heartfelt thanks to all our employees for their contributions to our success and express my gratitude to our Board of Directors for their continued support.
(1) EBITDA is a non-GAAP financial measure. See page 14 for the explanation of how we calculate Adjusted EBITDA and its reconciliation to net income (2) Excluding M2M (3) Following the change in organizational structure, the revenues of Turkcell Sigorta Aracılık Hizmetleri A.Ş. (Insurance Agency), which was previously managed under Financell, are now classified as "Other" in the Techfin segment as of the first quarter of 2023. (4) Including IPTV, OTT TV, fizy, lifebox and GAME+ (5) Our expectations for 2024 incorporate the effects of inflation accounting under IAS 29. These projections are based on assumptions regarding factors beyond our control, including key macroeconomic indicators such as inflation. Specifically, we are assuming an annual inflation rate of 43%, applied on a monthly basis, (previous estimate: 37%). This paragraph contains forward-looking statements that reflect our current estimates and expectations regarding market conditions across all of our businesses. However, there can be no assurance that these forward-looking statements will occur as anticipated. For a discussion of the various factors that could impact the outcome of these forward-looking statements, please refer to our 2023 annual report on Form 20-F filed with the SEC, specifically the risk factors section. (6) Excluding license fees

Guidance

Turkcell Iletisim Hizmetleri On Thursday November 7, 2024 Said Due To Higher-Than-Expected Inflation In The 2H Of The Year, Have Revised Our Year-End Inflation Forecast Upwards; Updating Our Revenue Growth Target For 2024 To ~ 7%. We Maintain Our EBITDA Margin Expectation At ~ 42% And Our Operational CapEx To Sales Ratio Target At ~ 23%

GWAY, RSLS and GV are among mid-day movers

Ikena Oncology (IKNA) just unveiled an update. Ikena Oncology, Inc. has elevated Jotin Marango, M.D., Ph.D. to the role of Chief Operating Officer ...

Ikena Oncology Promotes Jotin Marango to Chief Operating Officer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ikena Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ikna-stock-quote/">IKNA</a>) just reported results for the second quarter of 2024.<ul><li>Ikena Oncology reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -35 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ikna-stock-earnings-ikena-oncology-for-q2-of-2024/">IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024

Ikena Oncology GAAP EPS of -$0.28

In a report released today, David Nierengarten from Wedbush maintained a Hold rating on Ikena Oncology (IKNA – Research Report), with a price targe...

Wedbush Sticks to Its Hold Rating for Ikena Oncology (IKNA)

H.C. Wainwright analyst Andres Y. Maldonado has reiterated their bullish stance on IKNA stock, giving a Buy rating on August 9. Andres Y. Maldonado...

Ikena Oncology's IK-595 Shows Promising Potential as a Best-in-Class Dual RAF/MEK Inhibitor: Analyst Maintains Buy Rating

Ikena Oncology, Inc. (IKNA) has disclosed a new risk, in the Employment / Personnel category. Ikena Oncology, Inc. faces a significant business ris...

Ikena Oncology's Gamble: Slashing Workforce by Half Could Derail Strategic Plans

As of September 30, 2024, the Company had cash, cash equivalents, and marketable securities of $138.0 million. Published first on TheFly – the ulti...

iKena Oncology reports Q3 EPS (21c), consensus (27c)

Ikena Oncology GAAP EPS of -$0.21 beats by $0.06

Ikena Oncology, Inc. ( ($IKNA) ) has released its Q3 earnings. Here is a breakdown of the information Ikena Oncology, Inc. presented to its investo...

Comments

Ikena Oncology

Ikena Oncology (IKNA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO